UK Insulin Drugs & Delivery Devices Market Size
| Study Period | 2018 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Market Size (2024) | USD 499.83 Million |
| Market Size (2029) | USD 549.15 Million |
| CAGR (2024 - 2029) | 1.90 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
UK Insulin Drugs & Delivery Devices Market Analysis
The UK Insulin Drugs And Delivery Devices Market size is estimated at USD 499.83 million in 2024, and is expected to reach USD 549.15 million by 2029, growing at a CAGR of 1.9% during the forecast period (2024-2029).
One of the most significant risk factors for a severe course of COVID-19 is diabetes mellitus. This risk is believed to be influenced by several variables that are frequently present in diabetes mellitus, such as advanced age, a proinflammatory and hypercoagulable condition, hyperglycemia, and underlying comorbidities (hypertension, cardiovascular disease, chronic kidney disease, and obesity). Diabetes was quickly recognized as a risk factor for bad results during the COVID-19 pandemic. As a result, managing or delaying cases of type 2 diabetes has become more important than ever before. Several studies have confirmed that chronic diseases like diabetes are associated with adverse outcomes in COVID-19 patients.
An insulin infusion pump works as an alternative to the traditional system of daily injections or an insulin pen. Insulin infusion pumps reduce the large swings in blood glucose levels, lessen pain, and deliver more accurately than injections. The scheduling of meal timings is not required when using pumps. This makes infusion pumps more user-friendly for patients. Insulin therapy is also known as continuous subcutaneous insulin infusion (CSII). It is an efficient and flexible method of insulin delivery. The insulin pump has evolved and is more reliable than it was previously. CSII technology has witnessed numerous technological advancements, like the integration of continuous glucose monitoring with the pump. Now, insulin pumps can control the algorithm, automatically delivering the insulin after analyzing the blood glucose reading.
UK Insulin Drugs & Delivery Devices Market Trends
Rising diabetes prevalence
In the United Kingdom, the diabetic population is expected to witness a CAGR greater than 2% over the forecast period.
According to Diabetes UK, more than five million people in the United Kingdom are living with diabetes, which is an all-time high. Their data shows that more than 4.3 million people in the United Kingdom live with diabetes. Additionally, 850,000 people could be living with diabetes who are yet to be diagnosed. These registration figures for 2021-22 are up by 148,591 from 2020-2021. At this rate, the number of people with diabetes, including the undiagnosed population, is expected to rise to 6 million by 2030.
The rate of newly diagnosed Type 1 and Type 2 diabetes cases is increasing, mainly due to obesity, unhealthy diet, and physical inactivity. The rapidly increasing incidence and prevalence of diabetic patients and healthcare expenditure are indications of market growth. Leading manufacturers are focusing on technological innovations and developing advanced products to gain a substantial market share. There has been a significant rise in insulin delivery systems technology, ranging from insulin injections to insulin pumps. Technological innovations and advancements offer many conveniences in maintaining blood glucose levels.
Therefore, owing to the increasing diabetes prevalence, the studied market is anticipated to witness growth over the analysis period.
The Insulin Pumps Segment is Expected to Witness Highest Growth Rate Over the Forecast Period
An insulin pump is a device that automatically delivers insulin continuously, or whenever required. The pump mimics the human pancreas. The insulin infusion pump works as an alternative to the traditional system of daily injections or an insulin pen.
Insulin pumps held a major market share in the insulin delivery devices market in the current year, and it is expected to register a CAGR of more than 4.2% in the market during the forecast period because of the increasing technological advancement and its preference over other traditional methods due to continuous insulin administration. Insulin pump therapy is a well-established insulin administration method for type 1 diabetes (T1DM) people. Pumps are a validated, time-tested therapeutic option in T1DM at all ages, enabling near-physiological insulin delivery in situations where the pancreas does not produce insulin. There are even pump models with remote controls enabling parents of young children to either suspend or bolus insulin from a distance when the child is playing or eating. The insulin infusion pumps reduce the large swings in blood glucose levels, induce less pain, and deliver more accurately when compared to injections. These advantages of insulin pumps over the traditional delivery system are expected to boost the market.
The National Service Framework (NSF) program is improving services by setting national standards to drive up service quality and tackle variations in care. The Association of British HealthTech Industries (ABHI) launched a diabetes section, enabling diabetes technology companies to work together in the first forum of its kind. The ABHI group is for any health technology company with an interest in diabetes care, from CGM and insulin pumps to apps.
The use of continuous subcutaneous insulin infusion (CSII or insulin pumps) and continuous glucose monitoring systems (CGMs) has improved the care and quality of life for patients and is widely used in the ambulatory setting. Increasingly, this technology is also being used in the hospital setting. The COVID-19 pandemic emphasizes the need for good glycemic control in patients with diabetes, largely because most observational studies have reported that poorly controlled diabetes is associated with a higher risk for hospitalization and death from a viral illness. The frequency of monitoring glucose levels depends on the type of diabetes, which varies from patient to patient. Type-1 diabetic patients need to check their blood glucose levels at regular intervals, monitor their blood glucose levels, and adjust the insulin dosing accordingly, which is expected to drive the segment growth during the forecast period.
UK Insulin Drugs & Delivery Devices Industry Overview
The United Kingdom Insulin Drugs and Delivery Devices Market is consolidated, with few significant and generic players. Mergers and acquisitions that happened between the players in the recent past have helped the companies strengthen their market presence. Eli Lilly and Boehringer Ingelheim together have an alliance in developing and commercializing Basaglar (Insulin Glargine). Additionally, the players in the recent past helped the companies strengthen their market presence; for example, Novo Nordisk collaborated with Ypsomed to provide better insulin therapy solutions.
UK Insulin Drugs & Delivery Devices Market Leaders
-
Eli Lilly
-
Sanofi
-
Novo Nordisk
-
Medtronic
-
Ypsomed
*Disclaimer: Major Players sorted in no particular order
UK Insulin Drugs & Delivery Devices Market News
- May 2022: United Kingdom National Patient Safety Alert issued the alert about insulin leakage from the Roche Accu-Chek Insight insulin pump when paired with NovoRapid PumpCart insulin cartridges. UK regulator has taken safety action to reduce risks associated with Roche Accu-Chek Insight Insulin Pumps by issuing a national safety alert and outlining recommendations for patients.
- April 2022: NHS did the world's first test into a ‘sci-fi-like’ artificial pancreas. Almost 1,000 adults and children with type 1 diabetes have been given a potentially life-altering ‘artificial pancreas’ by the NHS in England as part of the first nationwide test into the effectiveness of this technology in the world.
UK Insulin Drugs & Delivery Devices Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Market Drivers
- 4.3 Market Restraints
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Bargaining Power of Suppliers
- 4.4.2 Bargaining Power of Consumers
- 4.4.3 Threat of New Entrants
- 4.4.4 Threat of Substitute Products and Services
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
-
5.1 Drug
- 5.1.1 Basal or Long-acting Insulins
- 5.1.1.1 Lantus (Insulin Glargine)
- 5.1.1.2 Levemir (Insulin Detemir)
- 5.1.1.3 Toujeo (Insulin Glargine)
- 5.1.1.4 Tresiba (Insulin Degludec)
- 5.1.1.5 Basaglar (Insulin Glargine)
- 5.1.2 Bolus or Fast-acting Insulins
- 5.1.2.1 NovoRapid/Novolog (Insulin aspart)
- 5.1.2.2 Humalog (Insulin lispro)
- 5.1.2.3 Apidra (Insulin glulisine)
- 5.1.2.4 FIASP (Insulin aspart)
- 5.1.2.5 Admelog (Insulin lispro Sanofi)
- 5.1.3 Traditional Human Insulins
- 5.1.3.1 Novolin/Mixtard/Actrapid/Insulatard
- 5.1.3.2 Humulin
- 5.1.3.3 Insuman
- 5.1.4 Combination Insulins
- 5.1.4.1 NovoMix (Biphasic Insulin aspart)
- 5.1.4.2 Ryzodeg (Insulin degludec and Insulin aspart)
- 5.1.4.3 Xultophy (Insulin degludec and Liraglutide)
- 5.1.4.4 Soliqua/Suliqua (Insulin glargine and Lixisenatide)
- 5.1.5 Biosimilar Insulins
- 5.1.5.1 Insulin Glargine Biosimilars
- 5.1.5.2 Human Insulin Biosimilars
-
5.2 Device
- 5.2.1 Insulin Pumps
- 5.2.1.1 By Technology
- 5.2.1.1.1 Tethered Insulin Pump
- 5.2.1.1.2 Tubless Insulin Pump
- 5.2.1.2 By Component
- 5.2.1.2.1 Insulin Pump Devices
- 5.2.1.2.2 Insulin Pump Reservoirs
- 5.2.1.2.3 Insulin Infusion sets
- 5.2.2 Insulin Pens
- 5.2.2.1 Cartridges in reusable pens
- 5.2.2.2 Disposable insulin pens
- 5.2.3 Insulin Syringes
- 5.2.4 Insulin Jet Injectors
6. MARKET INDICATORS
- 6.1 Type-1 Diabetes Population
- 6.2 Type-2 Diabetes Population
7. COMPETITIVE LANDSCAPE
-
7.1 COMPANY PROFILES
- 7.1.1 Novo Nordisk
- 7.1.2 Sanofi
- 7.1.3 Eli Lilly
- 7.1.4 Biocon
- 7.1.5 Julphar
- 7.1.6 Medtronic
- 7.1.7 Ypsomed
- 7.1.8 Becton Dickinson
- *List Not Exhaustive
- 7.2 COMPANY SHARE ANALYSIS
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityUK Insulin Drugs & Delivery Devices Industry Segmentation
Human insulin is administered to regulate blood sugar levels in individuals diagnosed with type 1 diabetes, a condition characterized by the body's inability to produce insulin and consequently unable to regulate blood sugar levels. It is also prescribed for individuals with type 2 diabetes, a condition where blood sugar levels are elevated due to the body's inadequate production or utilization of insulin, and oral medications alone are insufficient in managing the condition. There are several ways to give insulin subcutaneously, including a vial and syringe, an insulin pen, and continuous subcutaneous insulin infusion (CSII). The United Kingdom Insulin Drugs and Delivery Devices Market is segmented into Drugs (Basal or Long-acting Insulins, Bolus or Fast-acting Insulins, Traditional Human Insulins, Combination Insulins, and Biosimilar Insulins) and Devices (Insulin Pens, Insulin Pumps, Insulin Syringes, and Jet Injectors). The report offers the value (in USD million) and volume (in million mL) for insulin drugs and (in unit million) for the devices for the above segments.
| Drug | Basal or Long-acting Insulins | Lantus (Insulin Glargine) | |
| Levemir (Insulin Detemir) | |||
| Toujeo (Insulin Glargine) | |||
| Tresiba (Insulin Degludec) | |||
| Basaglar (Insulin Glargine) | |||
| Drug | Bolus or Fast-acting Insulins | NovoRapid/Novolog (Insulin aspart) | |
| Humalog (Insulin lispro) | |||
| Apidra (Insulin glulisine) | |||
| FIASP (Insulin aspart) | |||
| Admelog (Insulin lispro Sanofi) | |||
| Drug | Traditional Human Insulins | Novolin/Mixtard/Actrapid/Insulatard | |
| Humulin | |||
| Insuman | |||
| Drug | Combination Insulins | NovoMix (Biphasic Insulin aspart) | |
| Ryzodeg (Insulin degludec and Insulin aspart) | |||
| Xultophy (Insulin degludec and Liraglutide) | |||
| Soliqua/Suliqua (Insulin glargine and Lixisenatide) | |||
| Drug | Biosimilar Insulins | Insulin Glargine Biosimilars | |
| Human Insulin Biosimilars | |||
| Device | Insulin Pumps | By Technology | Tethered Insulin Pump |
| Tubless Insulin Pump | |||
| Device | Insulin Pumps | By Component | Insulin Pump Devices |
| Insulin Pump Reservoirs | |||
| Insulin Infusion sets | |||
| Device | Insulin Pens | Cartridges in reusable pens | |
| Disposable insulin pens | |||
| Device | Insulin Syringes | ||
| Insulin Jet Injectors |
UK Insulin Drugs & Delivery Devices Market Research FAQs
How big is the UK Insulin Drugs And Delivery Devices Market?
The UK Insulin Drugs And Delivery Devices Market size is expected to reach USD 499.83 million in 2024 and grow at a CAGR of 1.9% to reach USD 549.15 million by 2029.
What is the current UK Insulin Drugs And Delivery Devices Market size?
In 2024, the UK Insulin Drugs And Delivery Devices Market size is expected to reach USD 499.83 million.
Who are the key players in UK Insulin Drugs And Delivery Devices Market?
Eli Lilly, Sanofi, Novo Nordisk, Medtronic and Ypsomed are the major companies operating in the UK Insulin Drugs And Delivery Devices Market.
What years does this UK Insulin Drugs And Delivery Devices Market cover, and what was the market size in 2023?
In 2023, the UK Insulin Drugs And Delivery Devices Market size was estimated at USD 490.51 million. The report covers the UK Insulin Drugs And Delivery Devices Market historical market size for years: 2018, 2019, 2020, 2021, 2022 and 2023. The report also forecasts the UK Insulin Drugs And Delivery Devices Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
UK Insulin Drugs & Delivery Devices Industry Report
Statistics for the 2024 UK Insulin Drugs & Delivery Devices market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. UK Insulin Drugs & Delivery Devices analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
